VIVA
VIVA
November 05, 2019
2 min read
Save

IMPERIAL: Peripheral DES similar in patency, different in TLR at 2 years

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

LAS VEGAS — A peripheral drug-eluting stent with a polymer coating conferred lower rates of target lesion revascularization compared with a peripheral DES without a polymer coating, according to 2-year results from the IMPERIAL trial.

However, the patency advantage that the DES with polymer coating (Eluvia, Boston Scientific) held over the DES without coating (Zilver PTX, Cook Medical) at 1 year was no longer statistically significant at 2 years, researchers reported at VIVA 19.

At 2 years, the Kaplan-Meier estimates of primary patency were 83% for the Eluvia group and 77.1% for the Zilver group (log-rank P = .1), Osamu Iida, MD, associate director of the Cardiovascular Center and chief of coronary, endovascular and structure treatments at Kansai Rosai Hospital, Hyogo, Japan, said at a press conference.

“This is the highest patency rate reported in a major peripheral artery disease trial at 2 years,” he said.

The rate of clinically driven target lesion revascularization was lower in the Eluvia group (12.7% vs. 20.1%; log-rank P = .0495), he said.

There were no differences in all-cause mortality (Eluvia, 7.1%; Zilver, 8.3%; P = .6649) or freedom from major adverse events (Eluvia, 85.8%; Zilver, 79.9%; P = .1236) at 2 years, according to the researchers.

William Gray

“The safety was maintained, which is important given the recent [mortality signal] news about paclitaxel,” William Gray, MD, system chief of the division of cardiovascular disease at Main Line Health and president of Lankenau Heart Institute in Wynnewood, Pennsylvania, who was the principal investigator of IMPERIAL, said in an interview with Healio. “The efficacy difference appeared to be largely maintained as well. There continues to be a very good efficacy profile in terms of freedom from TLR.”

As Healio previously reported, IMPERIAL compared the DES in 465 patients (mean age, 68 years; 66% men) with Rutherford category 2, 3 or 4; at least one lesion in the native superficial femoral artery and/or the proximal popliteal artery; stenosis greater than 70%; vessel diameter between 4 mm and 6 mm; and total lesion length between 30 mm and 140 mm.

“The 1-year data were very important for efficacy and safety, but increasingly, operators, physicians, patients and payers want to see longer-term data. These 2-year data help shore up and validate the 1-year data. That is important for anyone considering use of the Eluvia device in their patient. Now that we have longer-term data, we can use these devices with some reassurance.”

Eluvia uses a lower dose of paclitaxel compared with Zilver (0.167 µg/mm2 vs. 3 µg/mm2), Iida said. – by Erik Swain

Reference:

Iida O, et al. Late-Breaking Clinical Trials. Presented at: VIVA 19; Nov. 4-7, 2019; Las Vegas.

Disclosure: The study was funded by Boston Scientific. Iida reports he received honoraria from Bard Peripheral Vascular, Boston Scientific, Cardiovascular Systems Inc., Medtronic and W.L. Gore and Associates.